Keyword: oral selective estrogen receptor degraders
News
03.07.2014
- Swiss-based Roche Holding AG plans to pay up to $1.73 billion to buy Seragon Pharmaceuticals, a privately-held US biotech company that researches breast cancer treatments. Roche...